Fig. 1

T cell diversity analysis in AML and non-tumor samples. a Normalized TCR CDR3 count in AML and non-tumor groups. The number of CDR3s was normalized by the number of total sequencing reads and one minus blast percentage (pathologically estimated tumor purity) in each sample. b TCR CDR3s per thousand (kilo) TCR reads (CPK, as a measure of clonotype diversity) in AML and non-tumor groups. c Barplot showing the ratio of virus-related β-CDR3 in AML and non-tumor groups. Virus-related β-CDR3 ratio was defined by the number of virus (cytomegalovirus, Epstein-Barr virus, and influenza)-related β-CDR3s divided by the total number of unique complete β-CDR3s in each group. d Comparison of β-CPK between samples with and without CBFB-MYH11 gene fusions. The p values in a, b, and d were calculated using the two-sided Wilcoxon rank-sum test. *p < 0.05, **p < 0.01, ***p < 0.001, n.s. indicates not significant